Independent register of U.S. FDA drug recalls · updated Oct 10, 2026
RxRecalls Get alerts
Class II · Moderate risk Terminated Initiated Jul 28, 2017 (9 years ago)

Famotidine USP 20 mg

Class II — Moderate risk. May cause temporary or reversible harm; serious harm unlikely.

Why it was recalled

Failed Tablet/Capsule Specification: out of specification for tablet weight.

Cause type: Failed specification

A physical or chemical test other than potency, dissolution, impurity or stability failed - pH, viscosity, appearance, tablet integrity, fill volume. A product outside its own specification may not perform as designed, even if the active ingredient is present. All failed specification recalls.

What was recalled

Famotidine USP 20 mg, 30 tablets bottle, Rx, PKG By; PD Rx Pharmaceuticals Incorporated Oklahoma City, OK 73127 --- NDC 55289-765-30

Affected NDC 55289-0765-30

Compare with the code on your package — it is the most precise check available.

Drug: Famotidine Category: Heartburn & Stomach Medication

Recalling firm
PD-Rx Pharmaceuticals, Inc.
NDC code
55289-765-30
Origin
OK, United States
Initiated by
Voluntary: Firm initiated
FDA recall number
D-1057-2017 · FDA notice

Check, then ask. Class II means harm is possible but usually temporary or reversible. Find the lot number on your package; if it matches, ask your pharmacist about a replacement. Do not simply stop a prescribed medication on your own - the gap can be riskier than the recall. This recall is now terminated, which means the firm has finished removing the affected product; anything on pharmacy shelves today should be unaffected.

Other Famotidine recalls

See all
Class I · High risk

Famotidine Injection

Microbial Contamination of Sterile Products; out of limit results obtained for endotoxin testing.

Ongoing Microbial contamination Fresenius Kabi USA, LLC NDC 63323-739-11 D-0182-2026
Class II · Moderate risk

Famotidine Tablets

Labeling: Label Error on Declared Strength: some cartons labeled and containing 20 mg may have an external label placed on the side of the carton indicating strength as 10 mg.

Terminated Labeling / mix-up Glenmark Therapeutics, Inc. NDC 72657-113-20 D-0939-2023
Class II · Moderate risk

Famotidine Tablets USP 40mg

Presence of foreign tablets/capsules: Famotidine 20mg and ibuprofen 400mg tablets were found in a lot of famotidine 40mg.

Terminated Particulate / foreign matter Aurobindo Pharma USA Inc. NDC 65862-860-99 D-0290-2021

Other recalls by PD-Rx Pharmaceuticals, Inc.

All 2017 recalls
Class II · Moderate risk

DULoxetine DR USP

CGMP Deviations: the presence of a Nitrosamine Drug Substance Related Impurity (NDSRI), N-Nitroso-Duloxetine above the interim acceptable intake limit

Terminated Nitrosamine impurity PD-Rx Pharmaceuticals, Inc. D-0163-2025
Class II · Moderate risk

Glimepiride USP

CGMP deviations.

Terminated cGMP deviation PD-Rx Pharmaceuticals, Inc. NDC 43063-0587-90 D-0559-2023